创新药ASCO月底召开，港股医疗ETF（159366）一度涨超2%

Group 1 - The core viewpoint of the news highlights the active performance of the innovative drug and medical sectors in the Hong Kong market, particularly driven by the upcoming ASCO annual meeting where significant clinical and research data will be disclosed by various innovative pharmaceutical companies [1][2] - The Hong Kong medical ETF (159366) saw a rise of 1.68%, with notable increases in constituent stocks such as Kangzheng Pharmaceutical (up 8.16%) and Tigermed (up 7.42%) [1] - The ASCO annual meeting, scheduled from May 30 to June 3, 2025, is recognized as one of the largest and most influential academic events in the field of oncology, expected to serve as a strong catalyst for the innovative drug industry [1] Group 2 - China National Pharmaceutical announced positive results for "Bemarituzumab combined with chemotherapy sequentially with Anlotinib for first-line treatment of sq-NSCLC," achieving a median progression-free survival (mPFS) of 10.12 months and a 36% reduction in the risk of disease progression/death [1] - The medical device sector is noted for its "hard technology" attributes, with companies in this space showing global competitiveness [3] - The trend in the medical device sector indicates multiple driving forces, including domestic substitution, technological innovation, centralized procurement clearance, and export expansion [3]